GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zoetis Inc (NYSE:ZTS) » Definitions » Cash-to-Debt
中文

Zoetis (Zoetis) Cash-to-Debt : 0.30 (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Zoetis Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Zoetis's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.30.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Zoetis couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Zoetis's Cash-to-Debt or its related term are showing as below:

ZTS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.16   Med: 0.3   Max: 0.52
Current: 0.3

During the past 13 years, Zoetis's highest Cash to Debt Ratio was 0.52. The lowest was 0.16. And the median was 0.30.

ZTS's Cash-to-Debt is ranked worse than
69.18% of 1048 companies
in the Drug Manufacturers industry
Industry Median: 0.945 vs ZTS: 0.30

Zoetis Cash-to-Debt Historical Data

The historical data trend for Zoetis's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Zoetis Cash-to-Debt Chart

Zoetis Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.29 0.49 0.52 0.44 0.30

Zoetis Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.44 0.31 0.25 0.26 0.30

Competitive Comparison of Zoetis's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Zoetis's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zoetis's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zoetis's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Zoetis's Cash-to-Debt falls into.



Zoetis Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Zoetis's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Zoetis's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zoetis  (NYSE:ZTS) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Zoetis Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Zoetis's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Zoetis (Zoetis) Business Description

Address
10 Sylvan Way, Parsippany, NJ, USA, 07054
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Executives
Roxanne Lagano officer: Executive Vice President C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Kristin C Peck officer: Executive Vice President C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Heidi C. Chen officer: Executive Vice President C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Robert J Polzer officer: Executive Vice President C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Soria Ester Banque officer: Executive Vice President C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Rimma Driscoll officer: Executive Vice President C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Jamie Brannan officer: Executive Vice President C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Vanessa Broadhurst director ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Willie M Reed director C/O ZOETIS, 100 CAMPUS DRIVE, FLORHAM PARK NJ 07932
Nicholas Ashton officer: Executive Vice President C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Roman Trawicki officer: Executive Vice President C/O ZOETIS INC., 100 CAMPUS DRIVE, FLORHAM PARK NJ 07932
Glenn David officer: SVP and Acting CFO C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Astorga Jeannette Ferran officer: Executive Vice President C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Catherine A. Knupp officer: Executive Vice President C/O ZOETIS INC., 100 CAMPUS DRIVE, FLORHAM PARK NJ 07940
Gregory Norden director 16640 CHESTERFIELD GROVE DRIVE, SUITE 200, CHESTERFIELD MO 63005

Zoetis (Zoetis) Headlines

From GuruFocus

Q3 2021 Zoetis Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q4 2021 Zoetis Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Zoetis Inc at Jefferies Pet Summit (Virtual) Transcript

By GuruFocus Research 01-23-2024

Q2 2021 Zoetis Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q2 2022 Zoetis Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024